Compositions and methods for treating and preventing coronary heart disease

• US 9,198,890 B2
• Filed: 04/30/2014
• Issued: 12/01/2015
• Est. Priority Date: 10/13/2011
• Status: Active Grant

• Current Assignee: Boston Heart Diagnostics Corporation (Eurofins Scientific SE)
• Original Assignee: Boston Heart Diagnostics Corporation (Eurofins Scientific SE)
• Inventors: Schaefer, Ernst J., Polisecki, Eliana
• Primary Examiner(s): Tate, Chris R
• Assistant Examiner(s): White, Douglas F
• Application Number:
  US14/265,862
• Publication Number:
  US 20140235607A1
• Time in Patent Office: 580 Days
• Field of Search: None
• US Class Current: 1/1
• CPC Class Codes: A61K 31/22 of acyclic acids, e.g. pravastatin
• CPC Class Codes: A61K 31/397 having four-membered rings, e.g. azetidine
• CPC Class Codes: C12Q 1/6827 for detection of mutation or polymorphism
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2600/106 Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
• CPC Class Codes: C12Q 2600/156 Polymorphic or mutational markers
• CPC Class Codes: C12Q 2600/172 Haplotypes

Abstract

The invention pertains to a method of determining a statin dosage for an individual in need of treatment with a statin, comprising determining a SLCO1B1 genotype from a nucleic acid sample of the individual, said genotype comprising the presence or absence of the SLCO1B1-056 polymorphism, and determining an ApoE genotype or phenotype identifying an ApoE polymorphism selected from the group consisting of ApoE2, ApoE3, ApoE4, and any combination thereof, wherein the combination of a SLCO1B1 genotype identifying the presence of the SLCO1B1-056 C polymorphism and the ApoE genotype or phenotype identifying one of the ApoE3/4 or ApoE4/4 genotypes indicates the statin dosage.

Claims

1. A method of characterizing a subject'"'"'s response to a cholesterol lowering therapy, the method comprising:

determining a level of cholesterol in a sample obtained from a patient;

conducting an assay in the sample to identify a polymorphism associated with statin efficacy, wherein the polymorphism is selected from the group consisting of a SLCO1B1 polymorphism, an Apolipoprotein E (ApoE) polymorphism, and a combination of a SLCO1B1 polymorphism and an ApoE polymorphism;

establishing weighted values based on the level of cholesterol and a genotype of the polymorphism; and

characterizing said patient'"'"'s likelihood of responding to a cholesterol lowering therapy based on said weighted values.

2. The method of claim 1, wherein the genotype of the SLCO1B1 polymorphism is selected from the group consisting of a C/T genotype, a C/C genotype, and a T/T genotype at the SLCO1B1 rs4149056 locus.

3. The method of claim 1, wherein the genotype of the ApoE polymorphism is selected from the group consisting of ApoE2/E2, ApoE2/E3, ApoE3/E3, ApoE3/E4, and ApoE4/E4.

4. The method of claim 1, further comprising categorizing said patient as a normal responder or a hypo-responder based on the weighted values.

5. The method of claim 4, further comprising the step of obtaining a plasma lathosterol/cholesterol ratio in the sample and assigned a weighted value to the ratio.

6. The method of claim 5, wherein said characterizing step further comprises the weighted value of the ratio.

7. The method of claim 6, wherein said weighted values contraindicate statin treatment.

8. A method of determining a cholesterol lowering therapy of a subject, the method comprising:

determining a level of cholesterol in a sample obtained from a patient;

conducting an assay in the sample to identify the presence or absence of a biomarker associated with statin efficacy, wherein the biomarker is one or more genes selected from the group consisting of SLCO1B1 and Apolipoprotein E (ApoE);

establishing weighted values based on the level of cholesterol and the presence or absence of the biomarker;

determining a dosage of a drug for reducing cholesterol based on the weighted value; and

administering the dosage of the drug to the patient.

9. The method of claim 8, wherein the weighted value of the biomarker is assigned based on a genotype of the biomarker.

10. The method of claim 8, wherein said cholesterol is LDL-cholesterol.

11. The method of claim 8, wherein the biomarker is a SLCO1B1 rs4149056 polymorphism.

12. The method of claim 8, wherein the biomarker is an ApoE polymorphism selected from the group consisting of an ApoE2 polymorphism, an APoE3 polymorphism, and an ApoE4 polymorphism at an ApoE locus.

13. The method of claim 11, wherein said SLCO1B1 rs4149056 polymorphism has a C/T genotype, a T/T genotype, or a C/C genotype.

14. The method of claim 12, wherein the ApoE polymorphism is a genotype selected from the group consisting of ApoE2/E2, ApoE2/E3, and ApoE3/E3.

15. The method of claim 8, wherein the drug for reducing cholesterol is selected from the group consisting of statin, ezetimibe, and combination thereof.

16. The method of claim 15, wherein said dosage of statin is between about 20 and about 40 milligrams.

17. The method of claim 15, wherein said dosage of statin is between about 40 and about 80 milligrams.